Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura

Blood

Volumn 103, Issue 4, 2004, Pages 1229-1236

  Kuwana, Masataka ^a   Nomura, Shosaku ^b   Fujimura, Kingo ^b   Nagasawa, Toshiro ^b   Muto, Yoshitomo ^b   Kurata, Yoshiyuki ^b   Tanaka, Shigeru ^b   Ikeda, Yasuo ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTIBODY; HUMANIZED CD40 LIGAND MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IDEC 131; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BLISTER; CELL SPECIFICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; DYSPNEA; FATIGUE; FEMALE; HOT FLUSH; HUMAN; HUMAN CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RHINORRHEA; SINGLE DRUG DOSE; T LYMPHOCYTE; T LYMPHOCYTE PROLIFERATION; THROMBOCYTE; THROMBOCYTE COUNT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING;

EID: 0842264044     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-2167     Document Type: Article

References (44)

1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995-1008.
2. Karpatkin S. Autoimmune (idiopathic) thrombocytopenic purpura. Lancet. 1997;349:1531-1536.
3. Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults. Br J Haematol. 2002;118:933-944.
4. McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med. 1997;126:307-314.
5. He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood. 1994;83:1024-1032.
6. Hürlmann-Forster M, Steiner B, von Felten A. Quantitation of platelet-specific autoantibodies in platelet eluates of ITP patients measured by a novel ELISA using purified glycoprotein complexes GPIIb/IIIa and GPlb/IX as antigens. Br J Haematol. 1997;98:328-335.
7. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T-cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura: role in production of anti-platelet autoantibody. J Clin Invest. 1998;102:1393-1402.
8. Kuwana M, Kaburaki J, Kitasato H, et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T-cells in patients with immune thrombocytopenic purpura. Blood. 2001;98:130-139.
9. Laman JD, Claassen E, Noelle RJ. Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol. 1996;16:59-108.
10. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2-17.
11. Datta SK, Kalled SL. CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum. 1997;40:1735-1745.
12. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science. 1993;261:1328-1330.
13. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol. 1995;154:1470-1480.
14. Howard LM, Miga AJ, Vanderlugt CL, et al. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest. 1999;103:281-290.
15. Howard LM, Dal Canto MC, Miller SD. Transient anti-CD154-mediated immunotherapy of ongoing relapsing experimental autoimmune encephalomyelitis induces long-term inhibition of disease relapses. J Neuroimmunol. 2002;129:58-65.
16. Im SH, Barchan D, Maiti PK, Fuchs S, Souroujon MC. Blockade of CD40 ligand suppress chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J Immunol. 2001;166:6893-6898.
17. Dumont FJ. IDEC-131 IDEC/Eisai. Curr Opinion Invest Drugs. 2002;3:725-734.
18. Brams P, Black A, Padlan EA, et al. A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation. Int Immunopharmacol. 2001;1:277-294.
19. Davis JC Jr, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001;28:95-101.
20. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T-cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:3251-3258.
21. National Cancer Institute Common Toxicity Criteria, version 2.0 (April 1999). Available at: http://ctep.cancer.gov/reporting/ctc.htmL. Accessed March 2003.
22. Keren DF, McCoy JP, Carey JL. Flow Cytometry in Clinical Diagnosis. Chicago, IL: American Society for Clinical Pathology Press; 2001.
23. Law C, Marcaccio M, Tam P, Heddle N, Kelton JG. High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med. 1997;336:1494-1498.
24. Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol. 2002;168:3875-3682.
25. Kuwana M, Okazaki Y, Kaburaki J, Ikeda Y. Detection of circulating B cells secreting platelet-specific autoantibody is useful in the diagnosis of autoimmune thrombocytopenia. Am J Med. 2003;114:322-325.
26. Kuwana M, Kawakami Y, Ikeda Y. Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura. Blood. 2003;101:621-623.
27. Chen FA, Williams SS, Fanslow WC, Bankert RB. Human antibody response in human peripheral blood leukocyte/severe combined immunodeficient chimeric model is dependent on B and T-cell costimulation via CD40/CD40 ligand. J Immunol. 1995;155:2833-2840.
28. Huang W, Sinha J, Newman J, et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. 2002;46:1554-1562.
29. Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48:719-727.
30. Emilia G, Morselli M, Luppi M, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood. 2002;99:1482-1485.
31. Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114:891-898.
32. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952-957.
33. Pierson RN, Crowe JEJ, Pfeiffer S, Atkinson J, Azimzadeh A, Miller GG. CD40-ligand in primate cardiac allograft and viral immunity. Immunol Res. 2001;23:253-262.
34. Homann D, Jahreis A, Wilfe T, et al. CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells. Immunity. 2002;16:403-415.
35. George J, Raskob G, Lichtin A, et al. Safety and effect on platelet count of single-dose monoclonal antibody to CD40 ligand (ANTOVA) in patients with chronic ITP [abstract]. Blood. 1998;92:707a.
36. Bussel J, Wissert M, Oates B, et al. Humanized monoclonal anti-CD40 ligand antibody (hu5c8) rescue therapy of 15 adults with severe chronic refractory ITP [abstract]. Blood. 1999;94:646a.
37. George J, Raskob G, Bussel J, et al. Safety and effect on platelet count of repeated doses of monoclonal antibody to CD40 ligand in patients with chronic ITP [abstract]. Blood. 1999;94:19a.
38. Biogen says it has stopped ongoing trials of anti-CD40 ligand monoclonal antibody. Biogen Inc. Press Release 1999 January 2.
39. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand [letter]. Nat Med. 2000;6:114.
40. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;39:591-594.
41. Henn V, Steinbach S, Büchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001;98:1047-1054.
42. 3 integrin-dependent mechanism. Nat Med. 2002;8:247-252.
43. IDEC Pharmaceuticals announces a clinical hold on ongoing clinical trials of its IDEC-131 antibody. IDEC Pharmaceuticals. Press Release 2002 June 10.
44. Ferrant JL, Wilson CA, Benjamin CD. Variation in the ordered structure of complexes between CD154 and anti-CD154 monoclonal antibodies. Mol Immunol. 2002;39:77-84.